Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Immune reconstitution after quadruplet therapy, autoSCT and MRD-adapted treatment cessation in NDMM

Luciano Costa • 26 Aug 2022
IMS 2022
Multiple Myeloma
MASTER

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares some insights into the findings of a correlative analysis on humoral immune reconstitution after quadruplet therapy, autologous transplantation, and measurable residual disease (MRD)-adapted treatment cessation in patients with newly diagnosed multiple myeloma (NDMM). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Luciano Costa

1:45
Challenges for community clinicians treating multiple myeloma
Luciano Costa • 11 Dec 2023
2:02
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma
Luciano Costa • 11 Dec 2023
2:40
Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myeloma
Luciano Costa • 11 Dec 2023
3:38
Outcomes for patients with multiple myeloma who have had first-line monoclonal antibody exposure
Luciano Costa • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals